首页> 外国专利> identification of hla-a2 t-cell epitopes derived from immature oncofetal antigen laminin receptor protein and uses thereof

identification of hla-a2 t-cell epitopes derived from immature oncofetal antigen laminin receptor protein and uses thereof

机译:源于未成熟胎胚抗原层粘连蛋白受体蛋白的hla-a2 t细胞表位的鉴定及其用途

摘要

Identification of T-cell epitopes presented by HLA-A2 derived from the laminae receptor protein immature of the oncofetal antigen and their use. The present invention relates to immunotherapeutic methods and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to cancer immunotherapy, in particular to various tumor entities, including malignant hematologic diseases. The present invention also relates to tumor-associated T-helper peptide epitopes, alone or in combination with other tumor-associated peptides, which serve as active pharmaceutical ingredients in antitumor immune response stimulating vaccine compositions. In particular, the present invention relates to two novel peptide sequences derived from oncofetal antigen immature laminin receptor (OFA / iLR) HLA class I or II molecules usable in vaccine compositions to elicit anti-tumor immune responses.
机译:由胎粪抗原未成熟的层状受体蛋白衍生的HLA-A2呈递的T细胞表位的鉴定及其用途。本发明涉及免疫治疗方法以及用于免疫治疗方法的分子和细胞。特别地,本发明涉及癌症免疫疗法,尤其涉及各种肿瘤实体,包括恶性血液病。本发明还涉及单独或与其他肿瘤相关肽组合的肿瘤相关T辅助肽表位,其在刺激抗肿瘤免疫应答的疫苗组合物中用作活性药物成分。特别地,本发明涉及衍生自可用于疫苗组合物中以引发抗肿瘤免疫应答的癌胚抗原未成熟层粘连蛋白受体(OFA / iLR)HLA I或II类分子的两个新的肽序列。

著录项

  • 公开/公告号BRPI0610841A2

    专利类型

  • 公开/公告日2010-07-27

    原文格式PDF

  • 申请/专利权人 IMMATICS BIOTECHNOLOGIES GMBH;

    申请/专利号BR2006PI10841

  • 发明设计人 MATTHIAS ZEIS;

    申请日2006-04-26

  • 分类号C07K14/47;A61K39;A61P35;C07H21;C07K14/705;C12N15;

  • 国家 BR

  • 入库时间 2022-08-21 18:47:22

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号